15 research outputs found
Cryptococcal Meningitis: Differences between Patients with and without HIV-Infection
No full textBackground: Cryptococcal meningitis is one of the most devastating infections, particularly in HIV-infected individuals. The increased use of immunosuppressants led to an increase in the incidence of cryptococcosis in HIV-uninfected individuals. This study aimed to compare the characteristics between groups. Methods: This retrospective cohort study was conducted from 2011 to 2021 in northern Thailand. Individuals diagnosed with cryptococcal meningitis aged ≥15 years were enrolled onto the study. Results: Out of 147 patients, 101 were individuals infected with HIV and 46 were non-infected. Factors associated with being infected with HIV included age < 45 years (OR 8.70, 95% CI 1.78–42.62), white blood cells < 5000 cells/cu.mm. (OR 7.18, 95% CI 1.45–35.61), and presence of fungemia (OR 5.86, 95% CI 1.17–42.62). Overall, the mortality rate was 24% (18% in HIV-infected vs. 37% in HIV-uninfected individuals, p-value = 0.020). Factors associated with mortality included concurrent pneumocystis pneumonia (HR 5.44, 95% CI 1.55–19.15), presence of alteration of consciousness (HR 2.94, 95% CI 1.42–6.10), infection caused by members of C. gattii species complex (HR 4.19, 95% CI 1.39–12.62), and anemia (HR 3.17, 95% CI 1.17–8.59). Conclusions: Clinical manifestations of cryptococcal meningitis differed between patients with and without HIV-infection in some aspects. Increasing awareness in physicians of this disease in HIV-uninfected individuals may prompt earlier diagnosis and timely treatment
Frequency of reversal agents and neurosurgical intervention classified by asymptomatic intracranial bleeding and symptomatic intracranial hemorrhage.
No full textFrequency of reversal agents and neurosurgical intervention classified by asymptomatic intracranial bleeding and symptomatic intracranial hemorrhage.</p
The Kaplan-Meier survival curve among no intracranial hemorrhage, asymptomatic intracranial hemorrhage and symptomatic intracranial hemorrhage groups in 90 days follow-up after recombinant tissue Plasminogen Activator (rtPA).
No full textWhen compared to non-ICH patients, asymptomatic ICH and symptomatic ICH was associated with an increased risk of 90-day mortality adjusted by age, HR 3.7, 95% CI 1.6–8.9, and HR 40.8, 95% CI 20.7–80.6, respectively.” Abbreviations: ICH, intracranial hemorrhage; HR, Hazard Ratios; CI, confidence interval.</p
90-day modified Rankin scale in no intracranial bleeding, asymptomatic intracranial bleeding and symptomatic intracranial bleeding.
No full textThis figure demonstrated the mRS among sICH, aICH, and no intracranial hemorrhage. The unfavorable mRS (mRS >2) were found in sICH comparing with aICH and no bleeding group (96.0%, 63.8%, and 40.50% respectively, P-value <0.001) Abbreviations: mRS, modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; aICH, asymptomatic intracranial hemorrhage.</p
Multivariable analysis of unfavorable outcomes defined as modified Rankin scale > 2 in patients with acute ischemic stroke and received rtPA.
No full textMultivariable analysis of unfavorable outcomes defined as modified Rankin scale > 2 in patients with acute ischemic stroke and received rtPA.</p
Characteristics of rtPA associated intracranial hemorrhage.
No full textCharacteristics of rtPA associated intracranial hemorrhage.</p
90-day outcomes (NIHSS >15, barthel index < 25, mortality) in no intracranial hemorrhage, asymptomatic intracranial hemorrhage, and symptomatic intracranial hemorrhage.
No full textAbbreviations: NIHSS, National Institute of Health Stroke Scale.</p
14-day outcomes (NIHSS >15, barthel index <25, mortality) in no intracranial hemorrhage, asymptomatic intracranial hemorrhage and symptomatic intracranial hemorrhage.
No full textAbbreviations: NIHSS, National Institute of Health Stroke Scale.</p
Risk factors of asymptomatic intracranial hemorrhage.
No full textRisk factors of asymptomatic intracranial hemorrhage.</p
Baseline characteristics of patients who received recombinant tissue plasminogen activator for acute ischemic stroke.
No full textBaseline characteristics of patients who received recombinant tissue plasminogen activator for acute ischemic stroke.</p
